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Development and evaluation of a one-step
multiplex real-time TaqMan® RT-qPCR assay
for the detection and genotyping of equine
G3 and G14 rotaviruses in fecal samples
Mariano Carossino1,2, Maria E. Barrandeguy2,3, Erdal Erol4, Yanqiu Li5 and Udeni B. R. Balasuriya1*
Abstract
Background: Equine rotavirus A (ERVA) is the leading cause of diarrhea in neonatal foals and has a negative impact
on equine breeding enterprises worldwide. Among ERVA strains infecting foals, the genotypes G3P[12] and G14P[12]
are the most prevalent, while infections by strains with other genomic arrangements are infrequent. The identification
of circulating strains of ERVA is critical for diagnostic and surveillance purposes, as well as to understand their molecular
epidemiology. Current genotyping methods available for ERVA and rotaviruses affecting other animal species rely on
Sanger sequencing and are significantly time-consuming, costly and labor intensive. Here, we developed the first one-
step multiplex TaqMan® real-time reverse transcription polymerase chain reaction (RT-qPCR) assay targeting the NSP3
and VP7 genes of ERVA G3 and G14 genotypes for the rapid detection and G-typing directly from fecal specimens.
Methods: A one-step multiplex TaqMan® RT-qPCR assay targeting the NSP3 and VP7 genes of ERVA G3 and G14
genotypes was designed. The analytical sensitivity was assessed using serial dilutions of in vitro transcribed RNA
containing the target sequences while the analytical specificity was determined using RNA and DNA derived from a
panel of group A rotaviruses along with other equine viruses and bacteria. The clinical performance of this multiplex
assay was evaluated using a panel of 177 fecal samples and compared to a VP7-specific standard RT-PCR assay and
Sanger sequencing. Limits of detection (LOD), sensitivity, specificity, and agreement were determined.
Results: The multiplex G3 and G14 VP7 assays demonstrated high specificity and efficiency, with perfect linearity. A
100-fold difference in their analytical sensitivity was observed when compared to the singleplex assays; however, this
difference did not have an impact on the clinical performance. Clinical performance of the multiplex RT-qPCR assay
demonstrated that this assay had a high sensitivity/specificity for every target (100% for NSP3, > 90% for G3 VP7 and >
99% for G14 VP7, respectively) and high overall agreement (> 98%) compared to conventional RT-PCR and sequencing.
Conclusions: This new multiplex RT-qPCR assay constitutes a useful, very reliable tool that could significantly aid in the
rapid detection and G-typing of ERVA strains circulating in the field.
Keywords: Rotavirus A, Equine rotavirus A, ERVA, One-step multiplex RT-qPCR, G-typing, G3, G14, Foal diarrhea
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Background
Equine rotavirus A (ERVA) has been identified as the
leading cause of diarrhea in neonatal foals < 3 months of
age and is responsible for 20 to 77% of foal diarrhea
cases, causing significant economic losses to the equine
breeding enterprises [1–7]. Rotaviruses are icosahedral,
non-enveloped viruses with a double-stranded, seg-
mented RNA genome (dsRNA) that belong to the family
Reoviridae (genus Rotavirus) [8, 9]. The ERVA genome
consists of 11 double-stranded RNA segments that en-
code for six structural proteins (VP1–4, 6 and 7) and six
non-structural proteins (NSP1–6). Segment 11 encodes
for two non-structural proteins (NSP5 and NSP6) [1,
10]. The rotavirus particle consists of a triple capsid, in-
cluding an outer capsid composed of VP7 and VP4, an
intermediate layer integrated by VP6 and an inner capsid
formed by VP1, VP2 and VP3 [11–13]. The two outer
capsid proteins, VP7 and VP4, are the most variable and
immunogenic proteins of the virus, which independently
elicit neutralizing antibodies following infection [1, 14].
Based on VP6 identity, rotaviruses are classified into
eight groups (A-H), from which group A rotaviruses
(RVA) are the leading cause of diarrhea in humans and
several animal species, including horses [15]. Group A
rotaviruses are further classified into G-types and
P-types according to the nucleotide sequence of the two
outer capsid proteins, VP7 and VP4, encoded by seg-
ments 9 and 4 of the genome, respectively [16]. Cur-
rently, 27 G-types and 35 P-types of RVA have been
recognized in several species including humans [9]. Thus
far, seven G-types (G3, G5, G6, G8, G10, G13 and G14)
and six P-types (P[1], P[3], P[7], P[11], P[12] and P[18])
have been identified among the RVA affecting horses,
with G3P[12] and G14P[12] being the most prevalent
and epidemiologically relevant genotypes [1, 2, 17–19].
Other genomic arrangements involving G- and P-types
different from G3/G14 and P[12] have been infrequently
described as infecting horses [1].
Group A rotaviruses are transmitted through the
fecal-oral route and infection in young foals is associated
with life-threatening watery diarrhea induced by a com-
bination of malabsorptive, osmotic and secretory mecha-
nisms [1, 20]. Control of ERVA infection in young foals
is achieved by the routine vaccination of pregnant mares
with an inactivated vaccine and strict husbandry/hy-
gienic practices to reduce the viral burden in the envir-
onment [1, 7, 21–23]. ERVA vaccines have been shown
to aid in the reduction of the incidence and severity of
diarrhea and also in the intensity and duration of viral
shedding, however they do not guarantee full protection
[1, 21, 22]. In addition, previous studies have shown that
there is significant antigenic variation among ERVA ge-
notypes, which leads to emergence of viruses that are
not neutralized by antibodies elicited by the current
vaccines [24–29]. Moreover, temporal and spatial varia-
tions in the prevalence and distribution of ERVA geno-
types has been previously reported [2, 29, 30]. Therefore,
it is important to perform genotypic characterization of
ERVA strains in order to understand the molecular epi-
demiology of ERVA, identify novel viral reassortants and
potential interspecies transmission, and assess vaccine
performance in the field. Currently, sequencing of VP7,
VP4 and other genome segments are required for geno-
typing circulating rotavirus strains. Conventional se-
quencing methodologies are generally labor intensive,
low throughput and costly. Real-time reverse transcrip-
tion quantitative polymerase chain reaction (RT-qPCR)
assays, particularly TaqMan® assays, offer a wide
spectrum of advantages compared to conventional
RT-PCR and sequencing. Some of these advantages in-
clude high throughput sample processing, increased sen-
sitivity and specificity, faster turnaround time, and
ability to multiplex. Even though several singleplex and
multiplex RT-qPCR assays have been developed for the
genotyping of human RVA genotypes [31–35], none have
been developed for the genotyping of animal rotaviruses
thus far, including ERVA. Here, we developed and evalu-
ated the performance of a one-step multiplex RT-qPCR
assay that allows the rapid detection of ERVA and the
genotyping of the most frequent G-types affecting horses
(G3 and G14) in fecal specimens. Overall, the one-step
multiplex RT-qPCR assay developed in this study can sim-
ultaneously detect and genotype G3 and G14 ERVA
strains with a performance equivalent to that of conven-
tional VP7-specific RT-PCR and Sanger sequencing.
Methods
Cell lines and viruses
MA-104 cells (ATCC® CRL-2378.1™, American Type
Culture Collection [ATCC], Manassas, VA, USA) were
maintained in Eagle’s minimum essential medium
(EMEM, Cellgro®, Mediatech Inc., Herndon, VA, USA)
with 200 mM L-glutamine and 10% inactivated fetal
bovine serum (Atlanta Biologicals, Flowery Branch,
GA, USA), 1 mM sodium pyruvate, 1X non-essential
amino acids, penicillin and streptomycin (100 U/ml
and 100 μg/ml) and 0.25 μg/ml of amphotericin B
(Gibco®, Carlsbad, CA, USA). Tissue culture fluid
(TCF) derived from MA-104 cells infected with ERVA
strain H2 (G3P[12]), ERVA strains RVA/Horse-tc/
ARG/E8701-5MCCH/2016/G14P[12], RVA/Horse-tc/
ARG/E8701–6MCBI/2016/G14P[12] and RVA/Horse-
tc/ARG/E8701-9MCGR/2016/G14P[12]; bovine RVA
(BRVA) strain NCDV-Lincoln, BRVA strain B223 and
simian RVA strain SA11 were used to assess the RT-qPCR
assay’s performance and specificity. Briefly, confluent
monolayers of MA-104 cells were inoculated with a 1:10
dilution of TCF containing trypsin-activated RVA in a
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minimal volume of maintenance media without FBS. After
1 h adsorption at 37 °C, monolayers were overlaid with
MA-104 medium containing 0.5 μg/ml of trypsin type IX
(Sigma-Aldrich, St. Louis, MO) and without FBS, and in-
cubated at 37 °C and 5% CO2 until 100% cytopathic effect
was observed (48 h post infection). Infected flasks were
frozen/thawed, clarified by centrifugation at 1,500 X g for
15min at 4 °C, aliquoted, and stored at − 80 °C.
Viral RNA and bacterial DNA
RNA and DNA from the following viruses and bacteria
associated with diarrhea in horses were included for
specificity evaluation of the ERVA-specific RT-qPCR
assay: TCF containing ERVA strains RVA/Horse-tc/
GBR/H2/1976/G3P[12], RVA/Horse-tc/ARG/E8701-5M
CCH/2016/G14P[12], RVA/Horse-tc/ARG/E8701–6M
CBI/2016/G14P[12] and RVA/Horse-tc/ARG/E8701-
9MCGR/2016/G14P[12] [29]; TCF containing bovine
RVA (BRVA) strains RVA/Cow/United States/NCDV-
Lincoln/1969/G6P6[1] and RVA/Cow/United States/
B223/1983/G10P8[11], TCF containing simian RVA
strain RVA/Simian-tc/ZAF/SA11-N5/1958/G3P[2], TCF
containing equine coronavirus strain NC99 [36], and
TCF containing equine rhinitis A (NVSL-060
0EDV8501) and B (NVSL-0610EDV85010) viruses.
ERVA strain H2, BRVA strains NCDV-Lincoln and
B223, and simian RVA strain SA11 were kindly pro-
vided by Dr. Viviana Parreño (INTA, Buenos Aires,
Argentina). Equine rhinitis viruses were obtained from
the National Veterinary Services Laboratories, United
States Department of Agriculture, Ames IA. DNA
samples from Escherichia coli, Salmonella enterica,
Rhodococcus equi, Neorickettsia risticii, Clostridium
perfringens, Clostridium difficile and Lawsonia intracel-
lularis were obtained from the University of Kentucky
Veterinary Diagnostic Laboratory (Table 1).
Fecal samples
A total of 177 fecal samples from diarrheic foals were
used in this study. Among these, 112 fecal samples were
collected from farms in central Kentucky [29] while 65
were from outbreaks of diarrhea that occurred in
Argentina between 2009 and 2014 [29, 30]. Ten percent
fecal suspensions in serum-free EMEM were prepared,
centrifuged at 2500 X g for 15 min at 4 °C, then filtered
through a 0.45 μm syringe filter. Aliquots of fecal
suspensions were stored at − 80 °C.
Nucleic acid isolation
Nucleic acid isolation was performed using the taco™
mini nucleic acid extraction system (GeneReach USA,
Lexington, MA, USA) as previously described [37]. Two
hundred microliters of 10% fecal suspension or tissue
culture supernatant was used as sample input and elu-
tion was performed with 200 μl of elution buffer and
stored at − 80 °C for future use.
RT-PCR amplification of ERVA VP7 gene (segment 9)
We established a VP7-specific (gene segment 9)
standard RT-PCR assay using the Qiagen One-Step
RT-PCR kit (Qiagen, Valencia, CA, USA) as previ-
ously described [38]. This assay was used as the
gold-standard method for ERVA detection in fecal
specimens [2, 39]. Briefly, a 25 μl reaction mixture
was composed of 5 μl 5X One-Step RT-PCR Buffer,
1 μl dNTP Mix, 1 μl of VP7-specific forward and re-
verse primers (Table 2, 20 μM, final concentration
0.8 μM), 1 μl of One-Step RT-PCR Enzyme Mix, 11 μl
of RNase-free water and 5 μl of template previously
subjected to a denaturing step at 95 °C for 5 min. The
cycling conditions included a reverse transcription
step (50 °C for 30 min) followed by a PCR activation
step at 95 °C for 15 min; 35 cycles of denaturation (94
Table 1 A panel of viruses and bacteria associated with diarrhea in horses, cattle and simians was used to assess the specificity of
the singleplex and multiplex RT-qPCR assays for detection and genotyping of ERVA
Viruses Bacteria
ERVA strain RVA/Horse-tc/GBR/H2/1976/G3P[12] Escherichia coli
ERVA strain RVA/Horse-tc/ARG/E8701-5MCCH/2016/G14P[12] Salmonella enterica
ERVA strain RVA/Horse-tc/ARG/E8701–6MCBI/2016/G14P[12] Rhodococcus equi
ERVA strain RVA/Horse-tc/ARG/E8701-9MCGR/2016/G14P[12] Neorickettsia risticii
BRVA strain RVA/Cow/United States/NCDV-Lincoln/1969/G6P6[1] Clostridium perfringens
BRVA strain RVA/Cow/United States/B223/1983/G10P8[11] Clostridium difficile
SRVA strain RVA/Simian-tc/ZAF/SA11-N5/1958/G3P[2] Lawsonia intracellularis
ECoV strain NC99
ERAV strain NVSL-0600EDV8501
ERBV strain NVSL-0610EDV85010
ERVA, equine rotavirus A; BRVA, bovine rotavirus A; SRVA, simian rotavirus A; ECoV, equine coronavirus; ERAV, equine rhinitis A virus; ERBV, equine rhinitis B virus
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°C for 1 min), annealing (47 °C for 1 min) and exten-
sion (72 °C for 2 min); and a final extension at 72 °C
for 2 min. PCR amplification products yielded a 1062
bp band following electrophoretic separation in a 1%
agarose gel.
Sequencing of ERVA VP7 gene for G-typing
Sequencing of the full-length VP7 gene (genome seg-
ment 9) was performed using a high fidelity One-Step
RT-PCR kit (Qiagen One-Step Ahead RT-PCR kit)
and the forward and reverse primers RVAVP7-Gra-5
and RVAVP7-Gra-3 (Table 2) as previously described
[29]. Briefly, a 25 μl reaction mixture was composed
of 10 μl 2.5X One-Step Ahead RT-PCR Master Mix,
1 μl of VP7-specific forward and reverse primers
(20 μM, final concentration 0.8 μM), 1 μl of 25X
One-Step Ahead RT-Mix, 7 μl of RNase-free water
and 5 μl of template previously subjected to a de-
naturing step at 95 °C for 5 min. The cycling condi-
tions included a reverse transcription step (45 °C for
15 min) followed by a PCR activation step at 95 °C for
5 min; 40 cycles of denaturation (95 °C for 15 s), an-
nealing (47 °C for 15 s) and extension (68 °C for 2
min); and a final extension at 68 °C for 5 min. PCR
products (1062 bp) were gel-purified using the QIA-
quick® Gel Extraction kit (Qiagen) according to the
manufacturer’s recommendations. DNA was submitted
for Sanger sequencing to a commercial company
(Eurofins Genomics LLC, Louisville, KY, USA). Both
DNA strands of VP7 amplicons were sequenced using
a panel of primers specified in Table 2. Sequence ana-
lysis was performed using Geneious R7 (Biomatters
Inc., Newark, NJ, USA). G-types were identified using
an automated genotyping tool for RVA (RotaC 2.0,
http://rotac.regatools.be/) [40].
Accession numbers
The nucleotide sequences derived from the fecal samples
and tissue culture fluid corresponding to ERVA strains
RVA/Horse-tc/ARG/E8701-5MCCH/2016/G14P[12], RVA/
Horse-tc/ARG/E8701–6MCBI/2016/G14P[12] and RVA/
Horse-tc/ARG/E8701-9MCGR/2016/G14P[12] utilized in
this study were deposited in GenBank under accession
numbers MG970165-MG970197, MH458234-MH458237,
KP116019-KP116049 and MF074190-MF074212.
Primer and probe design
Multiple alignments of full-length ERVA G3 (n = 17) and
G14 (n = 39) VP7 nucleotide sequences derived from Gen-
Bank were performed and consensus sequences obtained
using Geneious R7 software. G-type specific forward and
reverse primers and probes were designed towards
conserved regions specific to G3 VP7 and G14 VP7 gene
sequences using the PrimerQuest tool (https://www.
idtdna.com/Primerquest/home/Index) (Table 3). The pri-
mer and probe sequences were checked for specificity
using the NCBI Basic Local Alignment Search Tool
(BLAST; https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGR
AM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blas
thome) while self-annealing sites, hairpin loop formation
and 3′ complementarity were verified using the IDT Oli-
goAnalyzer tool (https://www.idtdna.com/calc/analyzer).
Synthesis of target NSP3 and VP7 genes and preparation
of in vitro transcribed RNA
ERVA-specific in vitro transcribed (IVT) RNA was synthe-
sized in order to determine the analytical sensitivity of the
ERVA-specific multiplex RT-qPCR assay. For this purpose,
a 493 nt insert containing the targeted regions (NSP3 [nt
position 963–1053], G3 VP7 [nt position 756–872] and
G14 VP7 [nt position 869–1011] derived from ERVA
strain H2 (NSP3 and G3 VP7) and ERVA strain FI23 (G14
VP7) (GenBank Accession numbers KM454500.1,
KM454497.1 and KM454508.1, respectively) were chem-
ically synthesized (GeneArt™ Gene Synthesis, Thermo-
Fisher Scientific, Regensburg, Germany) and cloned into
the pGEM®-3Z vector (Promega, Madison, WI) down-
stream of the T7 promoter (pRVA_NSP3G3G14) by a
commercial company. Subsequently, E. coli K12 DH10B™
Table 2 Primers used for RT-PCR amplification and sequencing of VP7 (genome segment 9) of ERVA
Primer name Target Nucleotide Position Sequence (5′ to 3′) Application
RVAVP7-Gra-5 VP7 1-20a GGCTTTAAAAGCGAGAATTT RT-PCR and sequencing
RVAVP7-Gra-3 VP7 1062–1,044a GGTCACATCATACAACTCT RT-PCR and sequencing
RVAVP7–389-R VP7 389-370a CCAGTAGGCCATCCTTTAGT Sequencing
RVAVP7-635-F VP7 635-659a GTCCACTTAATACACAAACTCTAGG Sequencing
RVAVP7-241-R VP7 245-220a GCAGTRTCCATTGAACCAGTAATTG Sequencing
RVAVP7-852-F VP7 856-879a GAYATAACGGCTGATCCAACTACG Sequencing
RVAVP7-881-F VP7 885-906a CTCCACAGATTGGACGAATGA Sequencing
anucleotide position based on GenBank Accession number KM454508.1
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T1R were transformed with the construct. Trans-
formed bacteria were cultured overnight at 37 °C with
shaking (270 rpm). Plasmid DNA was purified using
QIAprep Spin Miniprep kit (Qiagen, Valencia, CA)
following the manufacturer’s instructions and screened
by restriction digestion using the unique EcoRI,
BamHI, and HindIII restriction sites within and
flanking the insert. Sequence authenticity was con-
firmed by Sanger sequencing using T7 and SP6
promoter-specific primers. Plasmid DNA (1 μg) was
linearized using HindIII, purified using the High Pure
PCR Product Purification kit (Roche, Indianapolis, IN)
as instructed, and 0.5 μg of plasmid DNA was used for
in vitro transcription of the pRVA_NSP3G3G14 insert
using the Megascript® T7 Transcription kit (ThermoFisher
Scientific, Waltham, MA) following the manufacturer’s rec-
ommendations. Residual plasmid DNA was removed by di-
gestion with TURBO™ DNase (ThermoFisher Scientific) for
15min at 37 °C. The IVT RNA product was analyzed by
agarose gel electrophoresis, subjected to a clean-up proced-
ure using the MEGAclear™ Transcription Clean-Up kit
(ThermoFisher Scientific), and quantified using a Nano-
Drop 2000 spectrophotometer (ThermoFisher Scientific).
The pRVA_NSP3G3G14 IVT RNA was stored at − 80 °C
until used. The number of ERVA IVT RNA molecules per
microliter (copies/μl) was calculated according to the fol-
lowing formula:
The concentration of ERVA IVT RNA was adjusted to
107 copies/μl using nuclease-free water containing 40 ng/μl
of Ambion® Yeast tRNA (ThermoFisher Scientific), and
serially ten-fold diluted (107 - 0.1 IVT RNA copies/μl) using
nuclease-free water containing Ambion® Yeast tRNA.
ERVA-specific singleplex TaqMan® real-time RT-PCR assays
targeting G3 VP7, G14 VP7 and NSP3 genes
Primers and probes specific for ERVA G3 VP7 and G14
VP7 were designed as described above (Table 3). The reac-
tion was set up using the QuantiTect™ Probe RT-PCR kit
(Qiagen) following the manufacturer’s recommendations.
Briefly, the 25 μl reaction contained 12.5 μl of 2X Quanti-
Tect™ Probe RT-PCR Master Mix with ROX, 0.25 μl
QuantiTect™ RT Mix, 200 nM TaqMan® fluorogenic probe,
500 nM of each primer, and 5 μl of template RNA (previ-
ously subjected to a denaturing step at 95 °C for 5min).
Reverse transcription and amplification were carried out
in an ABI 7500 Fast Real-time PCR System (Applied Bio-
systems®, Life Technologies, Grand Island, NY). The pro-
gram included 30min at 50 °C (reverse transcription step),
15min at 95 °C (PCR initial activation step), followed by
45 cycles at 94 °C for 15 s (denaturation) and 60 °C for 1
min (combined annealing/extension). The NSP3-specific
(gene segment 7; pan-rotavirus A) assay was established in
the laboratory as previously described (Table 3) [41].
Number of IVT RNA molecules=μL ¼ Avogadro
0s number 6:022 1023ð Þ  IVT RNA concentration g=μLð Þ
IVT RNA molecular weight gð Þ
Table 3 Primers and probe combinations for the detection of rotavirus A (pan-rotavirus A, targeting the NSP3 gene) and specific
amplification of the VP7 gene of equine rotavirus A G3 and G14 genotypes
Name Target Nucleotide Position Sequence (5′ to 3′)
NVP3-FDeg1 NSP3 963-982a ACCATCTWCACRTRACCCTC
NVP3-R11 NSP3 1053-1,034a GGTCACATAACGCCCCTATA
NVP3-Probe1 NSP3 984-1,026a Cy5-ATGAGCACAATAGTTAAAAGCTAACACTGTCAA-BHQ2
RVA-G3-756F VP7 (G3)b 756–777 GATGTTACCACGACCACTTGTA
RVA-G3-872R VP7 (G3)b 872–854 AGTTGGATCGGCCGTTATG
RVA-G3-779P VP7 (G3)b 779–823 FAM-TGGGACCACGAGAGAATGTAGCTGT-TAMRA
RVA-G14-ARG869F VP7 (G14)c 869–885 ATCCGACTACGGCTCCA
RVA-G14-ARG1011R VP7 (G14)c 1011–990 TGCAGCAGAATTTAATGATCGC
RVA-G14-ARG886P VP7 (G14)c 886–915 HEX-CAGATTGGACGAATGATGCGTATAAATTGG-MGB
1Primers and probe name and sequences derived from Freeman et al., 2008
anucleotide position based on GenBank Accession number X81436
bnucleotide position based on GenBank Accession number KM454497.1
cnucleotide position based on GenBank Accession number KM454508.1
Cy5, cyanine 5; BHQ2, black hole quencher 2; FAM, 6-carboxyfluorescein; TAMRA, tetramethylrhodamine; HEX, hexachloro-fluorescein; MGB, minor groove binder
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ERVA-specific multiplex TaqMan® real-time RT-PCR assays
targeting G3 VP7, G14 VP7 and NSP3 genes
The G3 VP7, G14 VP7 and NSP3-specific assays were
multiplexed for the simultaneous identification of all
genotypes (pan-rotavirus A) and G-typing of ERVA. The
reaction was set up using the QuantiTect™ Multiplex
RT-PCR kit (Qiagen) following the manufacturer’s recom-
mendations. Briefly, the 25 μl reaction contained 12.5 μl of
2X QuantiTect™ Multiplex RT-PCR Master Mix with
ROX, 0.25 μl QuantiTect™ RT Mix, 200 nM of each Taq-
Man® fluorogenic probe, 200 nM of each primer, and 5 μl
of template RNA (denatured at 95 °C for 5min before be-
ing added into the reaction well). Reverse transcription
and amplification were carried out in an ABI 7500 Fast
Real-time PCR System (Applied Biosystems®). The pro-
gram included 20min at 50 °C (reverse transcription step),
15min at 95 °C (PCR initial activation step), followed by
40 cycles at 94 °C for 45 s (denaturation) and 60 °C for 75 s
(combined annealing/extension).
Statistical analysis
Standard curves were performed using IVT RNA (107 to
0.1 IVT RNA copies/μl). Coefficients of determination (R2)
were used to assess curve fitness. PCR amplification effi-
ciencies (%) were calculated after regression analysis using
the following formula: E ¼ ½10− 1slope−1  100. Limit of detec-
tion with 95% confidence (LOD95%) was determined by stat-
istical probit analysis (a non-linear regression model) using
the commercial software SPSS 14.0 (SPSS Inc., Chicago, IL,
USA) for all assays with 9 replicates per dilution ranging
from 105 to 1 IVT RNA copies/μl. Cycle threshold (Ct)
cut-off values were determined as the average Ct + 3 stand-
ard deviations of nine replicates of the endpoint dilution
[42]. Precision (within-run and between-run imprecision) of
the ERVA multiplex RT-qPCR assay was determined by per-
forming 9 replicates of IVT RNA containing 105, 104 and
103 RNA copies/μl on the same run (within-run impreci-
sion) or three replicates of IVT RNA containing 105, 104
and 103 RNA copies/μl tested on two different operational
days. The coefficient of variation (%) was determined for
each target concentration (G3 VP7, G14 VP7, and NSP3).
The performance of the ERVA multiplex RT-qPCR assay
was evaluated in fecal specimens and compared to the
VP7-specific RT-PCR and G-typing by Sanger sequencing.
Contingency tables (2 × 2) were generated to determine the
sensitivity, specificity and agreement (kappa statistic) of each
target within the multiplex RT-qPCR assay.
Results
Analysis of fecal samples by VP7-specific RT-PCR and
sequencing for determination of G-types
A total of 177 fecal samples were included in the study,
from which 92 samples were confirmed negative for
ERVA, while 85 were positive as determined by
VP7-specific standard RT-PCR [29, 30]. From the 85
ERVA-positive samples, 58 were collected in Argentina
and 27 were collected from the USA (Kentucky). Among
these, 41 were confirmed as G3 genotype while 44 were
confirmed as G14 genotype by sequencing of the VP7
gene. Extensive genetic and phylogenetic analysis of
these samples was recently published in a separate
article [29].
Analytical sensitivity and specificity of ERVA-specific
singleplex and multiplex RT-qPCR assays targeting G3
VP7, G14 VP7 and NSP3 genes
Analytical sensitivity of ERVA-specific singleplex RT-qPCR
assays
The analytical sensitivity of the ERVA-specific singleplex
and multiplex RT-qPCR assays was determined using a
ten-fold dilution series (3 replicates per dilution) of IVT
RNA (107 to 0.1 IVT RNA copies/μl) containing the target
sequences. Standard curves generated for the three targets
(G3 VP7, G14 VP7 and NSP3) under singleplex conditions
demonstrated perfect linearity (R2 > 0.99, Table 4 and
Fig. 1). Amplification efficiencies for the G3 VP7, G14
VP7 and NSP3 targets under singleplex conditions were
97, 98% and 103%, respectively. Detection rates (100%) for
the singleplex RT-qPCR assays are shown in Table 4. Pro-
bit analysis determined that the limits of detection 95%
(LOD95%) of the G3 VP7, G14 VP7 and NSP3 RT-qPCR
assays under singleplex conditions were 2.6, 5.7 and 27
copies/μl of IVT RNA and cycle threshold (Ct) cut-off
points were determined at 38, 39 and 34, respectively.
Analytical sensitivity of ERVA-specific multiplex RT-qPCR
assay
Standard curves generated for the three targets (G3 VP7,
G14 VP7 and NSP3) under multiplex conditions also
demonstrated perfect linearity (R2 > 0.99, Table 4 and Fig.
1). However, while the amplification efficiencies for the
G3 VP7 and NSP3 targets were ± 10% of that determined
under singleplex conditions (96 and 100%, respectively), a
lower amplification efficiency was determined for the G14
VP7 target when multiplexing (88%). Detection rates
(100%) for the multiplex RT-qPCR assay are shown in
Table 4. While the 100% detection rate limit for the NSP3
assay was equal between the singleplex and multiplex for-
mats, a 100-fold difference was observed for the G3 VP7
and G14 VP7 assays when these were multiplexed (Table
4). In comparison to the singleplex format, the LOD95%
were higher (716, 215 and 42 copies/μl of IVT RNA for
the G3 VP7, G14 VP7 and NSP3 targets, respectively). Ct
cut-off points were determined at 32, 34 and 34,
respectively.
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Analytical specificity of ERVA-specific singleplex and
multiplex RT-qPCR assays
To evaluate the analytical specificity of the singleplex
and multiplex RT-qPCR assays, a panel of rotavirus
strains along with other viruses and bacteria associated
with diarrhea in horses was used (Table 1). The
ERVA-specific G3 and G14 VP7 primer-probe combina-
tions were exclusively specific for the respective ERVA
genotype, did not cross-react between each other, did
not amplify other rotavirus genotypes from other species
and, interestingly, did not amplify the simian SA11 strain
(G3P2). The NSP3-specific primer-probe combination in
both singleplex and multiplex format was specific for
RVA and amplified the reference G3 and G14 strains of
ERVA as well as bovine and simian rotavirus strains as
previously reported [34]. None of the assays (G3 VP7, G14
Table 4 Analytical sensitivity analysis of singleplex and multiplex RT-qPCR assays for the detection and genotyping of equine
rotavirus A
Parameter Singleplex Multiplex
G3 G14 NSP3 G3 G14 NSP3
Slope −3.3936 −3.3732 − 3.2533 −3.4104 − 3.6377 −3.3175
Linearity (R2) > 0.99 > 0.99 > 0.99 > 0.99 > 0.99 > 0.99
Efficiency (%) 97 98 103 96.4 88 100
LOD95% (copies/μl) 2.6 5.7 27 716 215 47
Detection rate limit (100%, copies/μl) 10 10 100 1000 1000 100
Ct cut-off 38 39 34 32 34 34
LOD95%, limit of detection 95%; Ct, cycle threshold
Fig. 1 Comparison of the analytical sensitivity of the singleplex and multiplex RT-qPCR assays for the detection and G-typing of equine rotavirus
A. Ct, cycle threshold; IVT RNA, in vitro transcribed RNA
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VP7 and NSP3) amplified other viruses or bacteria associ-
ated with diarrhea in horses.
Precision assessment of the ERVA-specific multiplex RT-
qPCR assay
To evaluate the precision of the multiplex RT-qPCR
assay, within-run and between-run imprecision was de-
termined as recommended [42]. In all cases, the coeffi-
cient of variation was less than 3%, indicating that the
multiplex assay has a high repeatability (within-run) and
reproducibility (between-run) within the range of detec-
tion (Table 5).
Clinical performance of the ERVA-specific multiplex RT-
qPCR assay targeting G3 VP7, G14 VP7 and NSP3
The clinical performance of the ERVA-specific multiplex
RT-qPCR assay was evaluated in a total of 177 fecal
samples. The NSP3 (pan-RVA) assay was able to suc-
cessfully detect ERVA in all positive samples (85/85)
while no non-specific amplifications were observed in
negative samples (n = 92; Table 6a). Therefore, the assay
presented 100% sensitivity and specificity when com-
pared to the VP7-specific standard RT-PCR assay, along
with perfect agreement (kappa = 1). In the case of the
G3 VP7 assay, the assay was able to correctly genotype
38/41 ERVA G3 samples while non-specific amplifica-
tions were not observed in G3-negative samples (n =
136, Table 6b). Only three ERVA G3 positive samples
were unable to be genotyped by the multiplex assay,
however these were correctly genotyped by the
G3-specific singleplex RT-qPCR assay. Overall, the G3
VP7 assay presented a 92.7% sensitivity and 100% speci-
ficity when compared to the VP7-specific standard
RT-PCR assay, and a high agreement (98.31% [kappa =
0.951]). Finally, the G14 VP7 assay was able to correctly
identify 44/44 ERVA G14-positive samples and did not
amplify 132/133 ERVA G14 negative samples (Table 6c).
Consequently, the G14 VP7 assay presented a 100% sen-
sitivity and 99.2% specificity when compared to the
VP7-specific standard RT-PCR assay. The agreement be-
tween assays was high (99.44% [kappa = 0.985]). Regard-
ing the presumed false positive sample, although this
sample was determined to be an ERVA G3P[12] by
Sanger sequencing, it yielded a concurrent positive
amplification by the G3 and G14-specific RT-qPCR as-
says in both their singleplex and multiplex formats, sug-
gesting a possible co-infection with both genotypes of
ERVA.
Discussion
Group A rotaviruses are a primary cause of diarrhea in
children and animal species, including horses [1–6, 43,
44]. Even though seven G-types and six P-types of ERVA
have been identified in horses, the G3P[12] and
G14P[12] constitute the most epidemiologically relevant
genotypes [1, 2, 17–19]. Spatial as well as temporal fluc-
tuations between these predominant G-types (G3 and
G14) of ERVA circulating in equine populations have
been reported around the world [2, 30]. Interestingly,
the emergent pattern of G14 ERVA and the temporal
shift in the prevalent genotype has been observed in as-
sociation with the implementation of widespread vaccin-
ation programs in Argentina, Japan and Ireland [2, 30,
45, 46], which rely on the use of inactivated vaccines
containing only the H2 or HO-5 (G3P [12]) strains of
ERVA. The difficulties faced to date in establishing
cell-culture adapted G14P[12] or other strains of ERVA
has precluded their inclusion into vaccine formulations.
However, we have recently isolated and cell-culture
adapted, three G14P[12] ERVA strains with the potential
Table 5 Replication experiment to evaluate precision (within-
run and between-run imprecision) of the multiplex RT-qPCR
assays for the detection and genotyping of equine rotavirus A
Concentration
of target (IVT
RNA copies/μl)
Within-run imprecision Between-run imprecision
G3 G14 NSP3 G3 G14 NSP3
100,000 2.63% 1.29% 0.89% 2.92% 1.56% 0.97%
10,000 1.75% 0.74% 0.42% 2.19% 1.24% 0.83%
1,000 2.01% 0.51% 0.56% 2.52% 0.63% 0.68%
Table 6 Evaluation of the clinical performance of the multiplex
RT-qPCR assay for the detection and genotyping of equine
rotavirus A in fecal samples compared to VP7-specific RT-PCR
and sequencing (gold standard). (a) NSP3 (b) G3 VP7 and (c)
G14 VP7
a
VP7-specific RT-PCR
Positive Negative Total
NSP3-specific RT-qPCR Positive 85 0 85
Negative 0 92 92
Total 85 92 177
b
ERVA genotype G31
Positive Negative Total
G3-specific RT-qPCR Positive 38 0 38
Negative 3 136 139
Total 41 136 177
c
ERVA genotype G141
Positive Negative Total
G14-specific RT-qPCR Positive 44 1 45
Negative 0 132 132
Total 44 133 177
1Genotype determined by Sanger sequencing
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to be used as reference G14P[12] strains to study the
molecular biology of this genotype and perform vaccine
efficacy studies following heterologous challenge in the
future [29].
In light of the antigenic differences between ERVA ge-
notypes, their spatial and temporal distribution and their
impact on vaccine efficacy, molecular surveillance and
genotypification of circulating strains is critical. Since
genomic arrangements of ERVA other than G3P[12] and
G14P[12] are rare and the outer capsid protein VP7 con-
tains the major neutralizing epitopes, we developed a
one-step multiplex TaqMan® real-time RT-PCR for the
rapid detection and G-typing of the most prevalent ge-
notypes of ERVA (G3 and G14) in fecal specimens.
Compared to the conventional methods for ERVA geno-
typing (RT-PCR and Sanger sequencing), the multiplex
RT-qPCR assay has a significantly faster turnaround
time, is high-throughput, less labor-intensive and
exhibits a high sensitivity, specificity and agreement as
demonstrated in this study. While multiplexing did not
have an impact on the detection limit of the NSP3-tar-
get, the G3 and G14 targets demonstrated a 100-fold dif-
ference in their analytical sensitivity under multiplex
conditions. However, this difference in analytical sensi-
tivity did not have a significant impact on their clinical
performance on fecal specimens and only three G3
ERVA-positive samples were unable to be typed by the
multiplex RT-qPCR assay (false negatives). Interestingly,
these samples were correctly G-typed when the G3
VP7-specific assay was performed under singleplex con-
ditions. Such differences are probably due to a combin-
ation of low target nucleic acid in these fecal specimens
along with the 100-fold higher analytical sensitivity of
the singleplex compared to the multiplex assay. Despite
the low number of false negative samples (n = 3), all
three targets (G3 VP7, G14 VP7 and NSP3) showed a
high sensitivity and specificity (> 90%) along with a high
level of agreement (> 98%) in the clinical specimens
tested under multiplex conditions.
Noteworthy, a single sample, G-typed as G3 by means
of conventional methods (RT-PCR and Sanger sequen-
cing), exhibited specific amplification of both the G3
VP7 and G14 VP7 targets simultaneously under single-
plex and multiplex conditions. Although confirmation
would require RT-PCR using genotype-specific primers
or next generation sequencing, due to the fact that both
G3 and G14 ERVA strains were identified to be
co-circulating in the same farm during the same time
period, these results suggest that this dual-positive fecal
specimen most likely derived from a foal that was
co-infected with both G3 and G14 ERVA strains. Conse-
quently, this may indicate that the multiplex RT-qPCR
assay developed can be advantageous for the diagnosis
of co-infections with G3 and G14 strains of ERVA that
are currently challenging to identify. Further assessment
using spiked specimens is required in order to analyze
this multiplex RT-qPCR assay’s capability to identify
co-infected animals. Due to the lack of reference strains
and uncommon occurrence of other ERVA G-types,
these were not included in this study. Therefore, it is im-
perative to perform Sanger sequencing on those samples
that test positive for ERVA by amplification of NSP3 but
are not genotyped as G3 or G14 by the current assay. In
this regard, the genotyping assay developed here will fa-
cilitate rapid genotyping of circulating strains and iden-
tify rare G-types that can then be incorporated into this
assay depending on their epidemiological relevance.
Conclusions
In conclusion, the study presented herein describes the
development and evaluation of a one-step multiplex
TaqMan® RT-qPCR assay for the detection and genotyp-
ing of the most frequent G-types of ERVA infecting
horses. This assay demonstrated to have a high sensitiv-
ity, specificity and agreement compared to conventional
RT-PCR and sequencing, providing rapid and reliable
G-typing of ERVA strains. Therefore, this assay is highly
suitable for routine diagnostics as well as to aid current
surveillance programs of ERVA by rapidly characterizing
circulating strains. Finally, the number of specific targets
included in this assay can be updated and expanded as
other genomic arrangements of ERVA emerge and be-
come prevalent in equine populations.
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